Travere Therapeutics Inc Revenue Growth Rates (TVTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Travere Therapeutics Inc   (NASDAQ: TVTX)
 

TVTX's Revenue Growth by Quarter and Year

Travere Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TVTX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 169.58
1st Quarter March 127.20
FY 296.78

TVTXs Annual Revenue
Travere Therapeutics Inc 's Revenue in the fiscal year 2025 $ 490.73 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2024 $ 233.18 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2023 $ 145.24 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2022 $ 212.02 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2021 $ 227.49 millions




TVTX Revenue second quarter 2026 Y/Y Growth Comment
Travere Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue rise of 48.17% year on year, to $ 169.58 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue growth. While Travere Therapeutics Inc ' s Revenue jump of 48.17% ranks overall at the positon no. 761 in the second quarter 2026.


TVTX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 73.41 % 65.98 % -19.35 %
3rd Quarter September - 162.1 % 69.54 % -30.65 %
2nd Quarter June 48.17 % 111.47 % -9.35 % 10.21 %
1st Quarter March 55.63 % 97.56 % -27.41 % 17.53 %
FY   - 110.45 % 17.26 % -

Financial Statements
Travere Therapeutics Inc 's second quarter 2026 Revenue $ 169.58 millions TVTX's Income Statement
Travere Therapeutics Inc 's second quarter 2025 Revenue $ 114.45 millions Quarterly TVTX's Income Statement


TVTX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -21.33 % 18.9 % 21.46 %
3rd Quarter September - 44.05 % 16.22 % -37.86 %
2nd Quarter June 33.32 % 40.03 % 30.82 % 4.76 %
1st Quarter March -1.92 % 9.28 % -8.19 % 2 %
FY (Year on Year)   - 110.45 % 17.26 % -


Back to TVTX Growth rate Comparisons >> Back to TVTX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #161
Overall #761

Revenue Y/Y Growth Statistics
High Average Low
254.19 % 30.76 % -21.42 %
(Dec 31 2015)   (Jun 30 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #161
Overall #761
Revenue Y/Y Growth Statistics
High Average Low
254.19 % 30.76 % -21.42 %
(Dec 31 2015)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Travere Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20479.69 % 426.66 % -37.86 %
(Jun 30 2014)  


TVTX's II. Quarter Q/Q Revenue Comment
Travere Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 33.32% quarter on quarter, to $ 169.58 millions.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Travere Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 336.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #79
Overall #336
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #79
Overall #336
Revenue Q/Q Growth Statistics
High Average Low
20479.69 % 426.66 % -37.86 %
(Jun 30 2014)  


TVTX's II. Quarter Q/Q Revenue Comment
Travere Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 33.32% quarter on quarter, to $ 169.58 millions.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Travere Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 336.


Travere Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 591.33 $ 536.19 $ 490.73 $ 435.83 $ 333.87
Y / Y Revenue Growth (TTM) 77.12 % 96.03 % 110.45 % 114.22 % 87.94 %
Year on Year Revenue Growth Overall Ranking # 177 # 19 # 104 # 2868 # 0
Seqeuential Revenue Change (TTM) 10.28 % 9.27 % 12.6 % 30.54 % 22.06 %
Seq. Revenue Growth (TTM) Overall Ranking # 761 # 246 # 115 # 542 # 0


Cumulative Revenue growth Comment
Assuming the Travere Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Travere Therapeutics Inc would have reprted above average annual Revenue growth of 77.12% year on year, of $ 591 millions.
This marks a slow-down of the companys growth trends and from the 96.03% increase in Mar 31 2026.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 177.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 51
Overall # 177

Revenue TTM Y/Y Growth Statistics
High Average Low
254.19 %
 30.76 %
-21.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 161
S&P 500 # 761
Cumulative Revenue growth Comment
Assuming the Travere Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Travere Therapeutics Inc would have reprted above average annual Revenue growth of 77.12% year on year, of $ 591 millions.
This marks a slow-down of the companys growth trends and from the 96.03% increase in Mar 31 2026.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 177.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 51
Overall # 177

Revenue TTM Y/Y Growth Statistics
High Average Low
254.19 %
30.76 %
-21.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 161
S&P 500 # 761




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TVTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions


About Travere Therapeutics Inc Revenue Growth Rates (TVTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Travere Therapeutics Inc (CIK 1438533).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001438533-26-000063
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Travere Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.